{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:22:25Z","timestamp":1750004545317},"reference-count":26,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,6,1]],"date-time":"2014-06-01T00:00:00Z","timestamp":1401580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1016\/j.clinthera.2014.04.003","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T00:15:20Z","timestamp":1400112920000},"page":"953-960","source":"Crossref","is-referenced-by-count":10,"title":["Susceptibility of Staphylococcus aureus to Topical Agents in the United States: A Sentinel Study"],"prefix":"10.1016","volume":"36","author":[{"given":"Douglas J.","family":"Biedenbach","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel K.","family":"Bouchillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seth A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daryl J.","family":"Hoban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meredith","family":"Hackel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.04.003_bib1","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1517\/17460441.2013.779666","article-title":"Developing new antibacterials through natural product research","volume":"8","author":"Kirst","year":"2013","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.clinthera.2014.04.003_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/j.1749-6632.2011.06219.x","article-title":"Are pleuromutilin antibiotics finally fit for human use?","volume":"1241","author":"Novak","year":"2011","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clinthera.2014.04.003_bib3","first-page":"182","article-title":"The pleuromutilin antibiotics: a new class for human use","volume":"11","author":"Novak","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2014.04.003_bib4","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2174\/138955712798868968","article-title":"Pleuromutilin and its derivatives\u2014the lead compounds for novel antibiotics","volume":"12","author":"Tang","year":"2012","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.clinthera.2014.04.003_bib5","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1128\/AAC.01432-05","article-title":"Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci","volume":"50","author":"Jones","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2014.04.003_bib6","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2217\/17460913.2.6.591","article-title":"Retapamulin: a semisynthetic pleuromutilin compound for topical treatment of skin infections in adults and children","volume":"2","author":"Jacobs","year":"2007","journal-title":"Future Microbiol"},{"key":"10.1016\/j.clinthera.2014.04.003_bib7","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1586\/eri.09.7","article-title":"Microbiological profile of a new topical antibacterial: retapamulin ointment 1%","volume":"7","author":"Scangarella-Oman","year":"2009","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.clinthera.2014.04.003_bib8","first-page":"41","article-title":"Topical retapamulin in the management of infected traumatic skin lesions","volume":"5","author":"Shawar","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2014.04.003_bib9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1358\/dot.2008.44.2.1153446","article-title":"Retapmulin: a new topical antibiotic for the treatment of uncomplicated skin infections","volume":"44","author":"Parish","year":"2008","journal-title":"Drugs Today"},{"key":"10.1016\/j.clinthera.2014.04.003_bib10","doi-asserted-by":"crossref","first-page":"855","DOI":"10.2165\/00003495-200868060-00008","article-title":"Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections","volume":"68","author":"Yang","year":"2008","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2014.04.003_bib11","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.diagmicrobio.2006.05.009","article-title":"Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program 1998\u20132004","volume":"57","author":"Moet","year":"2007","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.clinthera.2014.04.003_bib12","first-page":"1198","article-title":"Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to Staphylococcus aureus","volume":"9","author":"Weinberg","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clinthera.2014.04.003_bib13","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1128\/AAC.00183-06","article-title":"Use of the surgical wound infection model to determine the efficacious dosing regimen of retapamulin, a novel topical antibiotic","volume":"50","author":"Rittenhouse","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2014.04.003_bib14","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1128\/AAC.50.2.765-769.2006","article-title":"Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes","volume":"50","author":"Kosowska-Shick","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2014.04.003_bib15","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2217\/fmb.11.69","article-title":"Emergence and spread of CFR-mediated multiresistance in staphylococci: an interdisciplinary challenge","volume":"6","author":"Wite","year":"2011","journal-title":"Future Microbiol"},{"key":"10.1016\/j.clinthera.2014.04.003_bib16","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/jac\/dkn266","article-title":"In vitro activity of retapamulin against Staphylococcus aureus isolates resistant to fusidic acid and mupirocin","volume":"62","author":"Woodford","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2014.04.003_bib17","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1093\/jac\/dkt015","article-title":"Detection and new genetic environment of the pleuromutilin-lincosamide-streptogramin A resistance gene Isa (E) in methicillin-resistant Staphylococcus aureus of swine origin","volume":"68","author":"Li","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2014.04.003_bib18","unstructured":"Clinical Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards\u2014ninth edition. http:\/\/www.google.com\/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CCcQFjAA&url=http%3A%2F%2Fwww.techstreet.com%2Fproducts%2Fpreview%2F1823012&ei=NbBGU86VM4Xi0gG1q4CABA&usg=AFQjCNHwgXsoDltX8H6jCoBAcKFUHHUBxA&sig2=YmR1g9QT4aMgUzdfugN3iQ&bvm=bv.64507335,d.dmQ&cad=rjt. Accessed April 10, 2014."},{"key":"10.1016\/j.clinthera.2014.04.003_bib19","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; twenty-second informational supplement. http:\/\/antimicrobianos.com.ar\/ATB\/wp-content\/uploads\/2012\/11\/M100S22E.pdf. Accessed April 10, 2014."},{"key":"10.1016\/j.clinthera.2014.04.003_bib20","unstructured":"Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests; approved standards\u2014eleventh edition. http:\/\/antimicrobianos.com.ar\/ATB\/wp-content\/uploads\/2012\/11\/01-CLSI-M02-A11-2012.pdf. Accessed April 10, 2014."},{"key":"10.1016\/j.clinthera.2014.04.003_bib21","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1128\/AAC.41.5.1137","article-title":"Interpretive criteria for testing susceptibility of staphylococci to mupirocin","volume":"41","author":"Finlay","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2014.04.003_bib22","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1128\/AAC.00399-08","article-title":"Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent","volume":"52","author":"Traczewski","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2014.04.003_bib23","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1128\/JCM.43.12.6212-6213.2005","article-title":"Quality control guidelines for susceptibility testing of retapamulin (SB-275833) by reference and standardized methods","volume":"43","author":"Ross","year":"2005","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.clinthera.2014.04.003_bib24","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1128\/JCM.00759-10","article-title":"Association of high-level mupirocin resistance and multidrug-resistant methicillin-resistant Staphylococcus aureus at an academic center in the Midwestern United States","volume":"49","author":"Cadilla","year":"2011","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.clinthera.2014.04.003_bib25","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1086\/520663","article-title":"Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit","volume":"45","author":"Jones","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2014.04.003_bib26","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1086\/605495","article-title":"Mupirocin resistance","volume":"49","author":"Patel","year":"2009","journal-title":"Clin Infect Dis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814002008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814002008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,10]],"date-time":"2019-08-10T13:18:13Z","timestamp":1565443093000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814002008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["S0149291814002008"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.04.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2014,6]]}}}